Revolution Medicines Holds Annual Stockholders Meeting

The latest announcement is out from Revolution Medicines ( (RVMD) ).

On June 26, 2025, Revolution Medicines held its annual meeting of stockholders, where three key proposals were voted on. The stockholders elected four Class II directors to serve until the 2028 annual meeting, ratified the appointment of PricewaterhouseCoopers LLP as the company’s independent auditor for the fiscal year ending December 31, 2025, and approved the compensation of the company’s named executive officers on a non-binding, advisory basis. These decisions are expected to impact the company’s governance and financial oversight positively.

The most recent analyst rating on (RVMD) stock is a Buy with a $82.00 price target. To see the full list of analyst forecasts on Revolution Medicines stock, see the RVMD Stock Forecast page.

Spark’s Take on RVMD Stock

According to Spark, TipRanks’ AI Analyst, RVMD is a Neutral.

Revolution Medicines has a moderate overall score primarily due to financial challenges such as declining revenues and persistent net losses, common in biotech firms. The technical analysis indicates a bearish trend, and the valuation remains unattractive with a negative P/E ratio. However, the positive strides in the RAS(ON) inhibitor pipeline and strong liquidity position partially offset these challenges, as highlighted in the recent earnings call.

To see Spark’s full report on RVMD stock, click here.

More about Revolution Medicines

Revolution Medicines, Inc. operates in the biotechnology industry, focusing on the development of targeted therapies for cancer treatment. The company is known for its innovative approach in creating small molecule inhibitors that target specific cancer pathways.

Average Trading Volume: 2,012,330

Technical Sentiment Signal: Sell

Current Market Cap: $7.15B

See more data about RVMD stock on TipRanks’ Stock Analysis page.